Kansenshogaku Zasshi
Online ISSN : 1884-569X
Print ISSN : 0387-5911
ISSN-L : 0387-5911
A Comparative Study of Cefepime for Bacterial Pneumonia
Atsushi SAITO, Yoshiteru SHIGENO, Yuei IRABU, Hiroshi FUKUHARA, Soukichi ONODERA, Hitoshi NAKANO, Tetsuo SHIMIZU, Nobuhiro SASAKI, Hirotaka HASHIZUME, Yuka FUJITA, Takashi HIROSHIMA, Eiichi SAKAI, Akira SAITO, Ichiro NAKAYAMA, Yohmei HIRAGA, Mitsuhide OHMICHI, Kazuo TAKEBA, Ken OSONOI, Miyoko SAITO, Hirohisa KURODA, Masao TAMURA, Kazuki KONISHI, Yoshiaki MORI, Akiho OBARA, Kazuo OBARA, Hitoshi KOBAYASHI, Junichi OGAWA, Kunio KUDO, Munehiko ISHII, Masakichi MOTOMIYA, Akira WATANABE, Yoshihiro HONDA, Yutaka TOKUE, Mitsunobu HONMA, Masataka KATSU, Keisuke KUGA, Junzaburou KABE, Hitoshi ARIOKA, Hiroko ARIOKA, Masaru KOYAMA, Kouichiro NAKATA, Yoshitaka NAKAMORI, Osamu SAKAI, Jingorou SHIMADA, Kohya SHIBA, Masaki YOSHIDA, Hiroichi TANIMOTO, Kazuo OBARA, Tetsuo OKAMURA, Hiroyuki KOBAYASHI, Toru SAKAYORI, Hiroshi OSHITANI, Hiroaki TAKEDA, Shoichiro IRIMAJIRI, Yasuo MATSUOKA, Mitsuo OBANA, Takao OKUBO, Hirotada IKEDA, Fumio MATSUMOTO, Iwao SAKURAI, Takayuki TAKAHASHI, Shigeki ODAGIRI, Hiroshi TAKAHASHI, Kenichi TAKAHASHI, Yasutsugu AMANO, Takashi SAKUMA, Masaaki ARAKAWA, Koichi WADA, Takashi KAWASHIMA, Masanaga TAKATO, Shigeyuki HOSHINO, Osamu SEKINE, Yasutoshi SUZUKI, Toshihiko TAKEUCHI, Yoshimitsu HAYASHI, Kazuhide YAMAMOTO, Toshihiko YAMAMOTO, Kanzo SUZUKI, Toru MATSUURA, Satoru ADACHI, Fumiyuki KUZE, Takako MURAYAMA, Nobuo INABA, Yoshio ODA, Akira KAGIOKA, Fumio MIKI, Rinzo SOEJIMA, Yoshihito NIKI, Jiro HINO, Masaru SUMI, Toshiharu MATSUSHIMA, Masayoshi KAWANISHI, Makoto KIMURA, Shunkichi HIRAKI, Yohichi WATANABE, Masashi ARAKI, Takao SASAKI, Yukio MATSUMOTO, Yuji SUGIMOTO, Hidemi TERAMOTO, Michiro YAMAKIDO, Kenji HASEGAWA, Takashi TSUYA, Kenichiro SADAMOTO, Masao KUWABARA, Masanobu OKADA, Kenichi ARITA, Masao DOI, Kazuhiro DAIDO, Jitsuro YANAGIDA, Kenichiro WATANABE, Yuichi ATA, Motohiro SUGIHARA, Masato YUKUTAKE, Kouichi AWAYA, Yoshihisa IHARA, Yoshihiro SAWAE, Nobuyuki SHIMONO, Yukio KUMAGAI, Takahito HIROSE, Kei SATO, Kohtaro OHIZUMI, Youichiro ICHIKAWA, Masako TANAKA, Yoshiyuki MITSUTAKE, Kazuma FUJINO, Mikio KUBUSHIRO, Toshihiro HIGASHI, Kohei HARA, Shigeru KOHNO, Hironobu KOGA, Mitsuo KAKU, Keizo MATSUMOTO, Kazunori OHISHI, Kiyoshi SHIMA, Shinobu TAKENAKA, Masaru NASU, Yoichiro GOTO, Tohru YAMAZAKI, Hiroyuki NAGAI, Takayoshi TASHIRO, Hiroshi NAGAOKA, Kaoru NAKAMA, Nobuya OGAWA, Nobuchika KUSANO
Author information
Keywords: bacterial pneumonia, cefepime, ceftazidime, comparative study
JOURNAL FREE ACCESS

1992 Volume 66 Issue 7 Pages 859-885

Details
Download PDF (2856K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

The efficacy, safety and usefulness of cefepime (CFPM), a new cephem antibiotic, in bacterial pneumonia, were evaluated in a comparative study against ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at a dose of 1.0 g (nominal potency) twice daily for 14 days, and the following results were obtained.
1. A total of 183 cases were enrolled in this study. Efficacy rates ( “good” or better responses) as evaluated by the subcommittee were 90.3%(65/72) in the CFPM group and 94.0%(63/67) in the CAZ group, with no significant difference between the 2 groups.
2. Efficacy rates ( “good” or better responses), as evaluated by attending physicians, (in the same bacterial pneumonia cases which were subjected to evaluation by the subcommittee) were 87.5%(63/72) in the CFPM group and 89.6%(60/67) in the CAZ group, with no significant difference between the 2 groups.
3. Bacteriologically, eradication rates were 96.9%(31/32) in the CFPM group and 96.7%(29/30) in the CAZ group with no significant difference between the 2 groups.
4. The incidence of side effects was 5.9%(5/85) in the CFPM group and 4.8%(4/84) in the CAZ group, with no significant difference between the 2 groups. No significant difference was also found between the 2 groups in the incidence of abnormal laboratory findings; 28.4%(23/81) of the case in the CFPM group and 34.1%(28/82) in the CAZ group.
5. As for overall usefulness of the drug in bacterial pneumonia cases, utility rates ( “useful” or better evaluations) as evaluated by the subcommittee were 88.9%(64/72) in the CFPM group and 92.5%(62/67) in the CAZ group. The rates as evaluated by investigators (in casesjudged as evaluable by the subcommittee) were 87.5%(63/72) and 85.1%(57/67), respectively. There were no significant differences between the 2 groups.
These results indicated that CFPM is very useful for the treatment of bacterial pneumonia.

Content from these authors
© The Japansese Association for Infectious Diseases
Previous article Next article
Favorites & Alerts

Recently viewed articles
Predecessor

Journal of the Japanese Association for Infectious Diseases

Share this page
feedback
 Top